KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Other financing activities (2017)

Pacira BioSciences has reported Other financing activities over the past 5 years, most recently at $11.0 million for Q1 2017.

  • Quarterly results put Other financing activities at $11.0 million for Q1 2017, changed N/A from a year ago — trailing twelve months through Dec 2017 was $11.0 million (changed N/A YoY), and the annual figure for FY2022 was $1.2 million, down 74.15%.
  • Other financing activities for Q1 2017 was $11.0 million at Pacira BioSciences, up from $7.2 million in the prior quarter.
  • Over the last five years, Other financing activities for PCRX hit a ceiling of $11.0 million in Q1 2017 and a floor of $7.2 million in Q1 2013.